Protocol Ledger

NCT04089566 · Phase III · COMPLETED

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Interventional Phase III clinical trial protocol NCT04089566 sponsored by Biogen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-26 Enrollment: 145 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04089566
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)145 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04089566
Protocol FieldVerified Registry Value
NCT IdentifierNCT04089566
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment145 participants (ACTUAL)
Registered Start Date2020-03-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI